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Abstract
Psoriasis (skin psoriasis, PsO) is a chronic inflammatory condition. In about one-third of cases, the joints are affected (pso-
riatic arthritis, PsA). Both conditions, especially PsA, profoundly impact patients’ health-related quality of life (HRQoL). 
To describe the impact of psoriasis on HRQoL and patients’ contact with the healthcare system in Sweden, Denmark, and 
Norway, the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP) asked 22,050 adults randomly selected 
in Sweden, Denmark and Norway if they had psoriasis. 1264 individuals who reported physician-diagnosed PsO/PsA were 
invited to the full survey; 1221 responded (74.6% diagnosed with PsO alone; 25.4% with PsA ± PsO). Respondents with 
PsA most frequently consulted a rheumatologist; however, 14.3% had never seen a rheumatologist. Respondents with PsO 
alone most frequently consulted a general practitioner and 10.7% had never seen a dermatologist (although those with severe 
symptoms visited dermatologists more often). Negative impacts on HRQoL were reported by 38.1% of respondents with PsO 
[mostly limitations on clothing (22.6%), sleep disorders (16%), and depression/anxiety (16%)] and by 73% of respondents 
with PsA [mostly limitations on clothing (41.8%), sports/leisure (44.0%), or daily routine (45.1%) and sleeping disorders]. 
Absence from work/education was more common with PsA ± PsO (51.9%) than PsO alone (15.1%). In this survey in Sweden, 
Denmark, and Norway, the impact of psoriasis on the respondents’ HRQoL was profound and was greater for PsA than for 
PsO, as was sickness absence. Sleeping disorders and depression were common and should not be overlooked.
Keywords Psoriasis · Psoriatic arthritis · Quality of life · Depression
Introduction
Psoriasis (PsO) is a chronic inflammatory skin condition 
that, in many cases, requires life-long monitoring and man-
agement. In about one-third of cases, manifestation of the 
disease is not limited to the skin, but also affects the joints, 
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causing psoriatic arthritis (PsA) [8, 20]. Both conditions, 
especially PsA, have a profound impact on the patient’s 
health-related quality of life (HRQoL), which is often under-
estimated [16]. An understanding of HRQoL in PsO/PsA, 
and its relationship with disease severity and response to 
treatment, is important in establishing better approaches to 
the care and treatment of patients with these conditions.
The Multinational Assessment of Psoriasis and Psoriatic 
Arthritis (MAPP) survey confirmed the profound impact of 
PsO and PsA on patients’ daily lives, but did not include 
any Nordic countries [12]. Estimates from several studies 
carried out since 2000 suggest that the prevalence of PsO in 
Scandinavia is relatively high-ranging from 3.9 up to 11.5% 
[5, 9, 13, 15]. The NORdic PAtient survey of Psoriasis and 
Psoriatic arthritis (NORPAPP) was conducted to gain a bet-
ter understanding of the challenges faced by people living 
with PsO and PsA in Sweden, Denmark, and Norway [4]. 
The specific objective of this report is to describe and com-
pare patients’ perceptions of the impact of PsO alone and 
PsA with or without PsO (PsA ± PsO) on their HRQoL and 
physician contact in these countries. The NORPAPP survey 
provided us with a large database of 1264 respondents with 
PsO and/or PsA.
Materials and methods
Details of the methodology have been previously described 
[4]. The survey was conducted in Sweden, Denmark, and 
Norway by the international market research firm YouGov 
between November and December 2015, following the Inter-
national Chamber of Commerce (ICC)/European Society for 
Opinion and Marketing Research (ESOMAR) International 
Code on Market, Opinion and Social Research and Data 
Analytics. The survey was conducted in accordance with 
the ethical standards required in each participating country. 
Briefly, an initial survey population of 22,050 adults (aged 
18–74 years), randomly selected from YouGov’s panels of 
potential survey participants in each country, were asked if 
they had any type of PsO or PsA. Active sampling was used 
to ensure that the initial survey population was representa-
tive of the adult population in each country in terms of age 
and gender. All 1264 individuals who reported physician-
diagnosed PsO or PsA were invited to participate in the full 
survey. Participants did not need to specify what type of phy-
sician had provided their diagnosis, nor did they have to be 
under the current care of a physician. The survey was com-
pleted via an online link sent to participants by email and 
the response rate was 96.6% (1221 respondents). The sur-
vey questions covered a broad range of impacts on HRQoL, 
expanding on the standard dermatology QoL measurement 
tools to include sleep disorders, hygiene, and depression/
anxiety (Online Resource 1).
The respondents’ reported five-level self-perception of 
severity was dichotomized to ‘non-severe’ (“not severe 
at all” or “not particularly severe”) and ‘severe’ (“quite 
severe”, “very severe”, or “extremely severe”). Body sur-
face area (BSA) was used to define the extent of PsO skin 
involvement. Respondents were asked to report the num-
ber of palms covered with PsO (one palm being equivalent 
to 1% of BSA). These two measures were only moderately 
correlated (Spearman’s rank correlation = 0.42) as has been 
reported previously [4]. Since the NORPAPP survey was 
designed to investigate respondents’ perspectives, the sub-
jective severity measure was used to define subgroups in the 
analyses reported below.
Responses to a multipart HRQoL impact question (Online 
Appendix A, Q14), which were on a five-point Likert scale, 
were dichotomised into ‘no strong impact’ (answers 1–3 or 
“do not know”) and ‘strong impact’ (4 or 5). For the analysis 
of the frequency of absences from work/education (Online 
Appendix A, Q16 Have you been absent from work or school 
in the past 12 months due to your psoriasis/psoriatic arthri-
tis?) responses “yes, a couple of days in the past year” and 
“yes, only once in the past 12 months” were grouped into 
‘yes, a couple of days in the past year or less’; and responses 
“yes, a couple of days per week” and “yes, a couple of days 
per month” were grouped into ‘yes, a couple of days per 
month or more’.
Data from Sweden, Denmark, and Norway were ana-
lysed together as a pooled data set. Respondent data were 
weighted to match the demographics (gender and age) of 
each country. The significance of deviations in responses 
between subgroups based on country, diagnoses, age, sex, 
perceived severity of their condition, and patient group 
membership was assessed using Chi-squared tests and z tests 
with Bonferroni corrections (total α = 0.05) for comparisons 
of multiple answers within each question.
Results
Study population
Population demographics and patterns of treatment use have 
been reported previously [4, 19]. In brief, 48.9% were male 
and 55.1% were aged 45–74 years. PsO alone was diag-
nosed in 74.6% of respondents; the remaining respondents 
reported a diagnosis of PsA alone (10.3%) or PsA with PsO 
(PsA + PsO, 15.1%). Overall, 21.0% reported membership of 
a patient organisation: 14.6% of respondents with PsO alone, 
46.5% with PsA alone, and 35.3% with both conditions. In 
their subjective judgement, most of the respondents (72.7%) 
with PsO alone considered their condition to be non-severe 
whereas 26.9% considered their condition to be severe. The 
severity of PsA symptoms was perceived to be greater than 
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the severity of PsO symptoms: 38.9% of the respondents 
with PsA ± PsO considered their condition to be non-severe 
and 58.7% considered their condition to be severe. The 
most frequently used treatments were emollients and topi-
cal steroids, with the current use reported by 49% and 38%, 
respectively, of respondents with PsO and by 48% and 35% 
of respondents with PsA + PsO. Systemic treatment use was 
reported by 14.6% of respondents with PsO-only and 58.5% 
of respondents with PsA (including use of biologic agents 
by 8.1% and 31.8%, respectively).
Contact with healthcare systems
Most of the respondents (81.7%) had seen a healthcare pro-
fessional (HCP) within the previous 3 years. A substantial 
minority of responders with PsO alone (22.4%) had not seen 
an HCP for their condition in over 3 years. Corresponding 
figures for respondents with PsA alone and PsA + PsO were 
5.6% and 6.7%.
Medical specialty treating PsO or PsA
Overall, respondents with PsO alone most frequently con-
sulted a general practitioner (GP) or a dermatologist for their 
PsO symptoms (Fig. 1a). In Norway, it was more common 
to see a GP than a dermatologist, whereas, in Sweden and 
Denmark, it was equally common to see either a GP or a 
dermatologist (data not shown). Among respondents with 
PsO alone, those considering their PsO to be severe were 
more likely to see a dermatologist instead of a GP (Fig. 1a). 
Respondents with PsA ± PsO, irrespective of perceived 
severity, were most likely to report seeing a rheumatologist 
(Fig. 1b).
Among respondents with PsO alone, 10.7% had never 
seen a dermatologist. Among respondents with PsA ± PsO, 
14.3% had never seen a rheumatologist. Within the previ-
ous year, 38.9% of respondents with PsO alone had seen a 
dermatologist and 60.9% of respondents with PsA ± PsO had 
seen a rheumatologist.
Reasons for seeing an HCP at the most recent visit
For respondents with PsO alone, the most commonly 
reported reason for last seeing an HCP regarding PsO 
symptoms was renewal of a prescription, followed by 
the discussion of treatment options—the frequencies of 
these reasons were not significantly influenced by severity 
(Fig. 2a). Respondents with severe symptoms were more 
than twice as likely to have last seen an HCP for worsening 
of symptoms, testing or results, light therapy, and concerns 
regarding side-effects from medication than those with 
non-severe symptoms (Fig. 2a). Side-effects were men-
tioned by a total of 13.9% of respondents with severe PsO 
symptoms: 6.5% actually had side-effects and 7.4% wished 
to discuss possible side-effects. Side-effects were men-
tioned by 3.0% of respondents with non-severe symptoms; 
1.0% actually had side-effects and 2.0% wished to discuss 
possible side-effects. Respondents who were members of a 
patient organisation were also significantly more likely to 
talk about possible side-effects than non-members (19.5% 
Fig. 1  Healthcare professionals (HCPs) most frequently consulted 
by respondents. a HCP consulted for psoriasis (PsO) symptoms 
by respondents reporting PsO alone. b HCP consulted for psoriatic 
arthritis (PsA) symptoms by respondents reporting PsA with or with-
out PsO (PsA ± PsO). Results are shown for all respondents in each 
diagnosis group and are split according to the respondent’s self-per-
ception of the severity of their condition. (Q19. What is the medical 
specialty of the healthcare professional that you see most often for 
your…?). *Significant difference between severity groups (Bonfer-
roni-corrected z tests, total α = 0.05). aOther HCP for PsO includes: 
nurse, rheumatologist, allergist, unspecified HCP, physiotherapist, 
and orthopaedist; other HCP for PsA includes: physiotherapist, ortho-
paedist, nurse, and allergist. In total, 3% of respondents in each group 
did not know or declined to answer
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versus 3.5%, p < 0.05): 7.6% actually had side-effects and 
11.9% wished to discuss possible side-effects.
Respondents with PsA ± PsO were most likely to have 
last seen an HCP regarding PsA symptoms for follow-up and 
testing and results (Fig. 2b). Respondents with severe PsA 
symptoms were significantly more likely than those with 
non-severe symptoms to have wanted to discuss treatment 
options with their physicians (Fig. 2b). Side-effects from 
medication were given as a reason for their most recent HCP 
visit by 24.4% of respondents with severe PsA symptoms: 
10.0% actually had side-effects and 14.4% wanted to discuss 
possible side--effects. Of the respondents with non-severe 
symptoms, 6.3% actually had side-effects and 5.8% wished 
to discuss possible side-effects.
Quality of life
Impact of symptoms on daily life
Although the majority of respondents (61.9%) reporting PsO 
alone indicated that their disease did not strongly impact 
their activities of daily living, the reverse was true for 
respondents with PsA ± PsO; a majority (73.0%) reported 
at least one impact and 44.5% reported four or more impacts 
(Fig. 3).
For respondents with PsO alone, the most commonly 
reported strong negative impact was on respondent’s choice 
of clothing or shoes. Slightly less common, but still affecting 
about a sixth of the respondents with PsO alone, were sleep 
disorders and depression and/or anxiety (Fig. 3).
For respondents with PsA ± PsO, strong negative impacts 
related to daily routine, leisure/sports, sleeping disorders, 
and limitations on dress were reported by over 40% of 
respondents (Fig. 3).
Among respondents who had not seen a dermatologist or 
rheumatologist within the prior year, most (69.4%) reported 
zero impacts of their condition on daily activities. Of those 
respondents who had seen a dermatologist or rheumatolo-
gist within the prior year, 32.7% reported zero impacts and 
38.4% reported four or more impacts on their daily activities 
(compared to 9.9% for those who had not seen a specialist).
Influence on work/career or education
For those respondents for whom it was applicable (82.2% 
of respondents were working or studying; 94.1% of 
those aged 18–44, and 72.5% of those aged 45–74), the 
frequency of absences from work or school in the pre-
vious 12 months is shown in Fig. 4. Diagnosis signifi-
cantly influenced absences from work or school (Fig. 4a). 
Respondents with PsA ± PsO were more likely to have 
reported absences than those with PsO alone. Respond-
ents’ perception of severity was also strongly related to 
absences (Fig. 4b). Respondents using systemic treatments 
were much more likely to have been absent than those 
only using topical treatments (Fig. 4c). The age group of 
respondents also showed significant effects; those aged 
18–44 years were more likely to be occasionally absent 
than those aged 45–74, although long-term sick-leave rates 
were not significantly different between the age groups 
(Fig. 4d; note that non-working/studying respondents were 
excluded from these data). Respondents who were mem-
bers of patient groups were much more likely to be absent 
than those who were not (Fig. 4e), as were respondents 
Fig. 2  Reasons for the most recent consultation with a physician: a 
for psoriasis (PsO) symptoms, among respondents with PsO alone, b 
for psoriatic arthritis (PsA) symptoms among respondents reporting 
PsA with or without PsO (PsA ± PsO). Note that respondents could 
select more than one response to this question. (Q22/23. If you think 
about the last time you were in contact with a physician for your pso-
riasis (on skin, nails, or scalp)/psoriatic arthritis. What were the main 
reasons that you were in contact with the physician? *Significant dif-
ference between severity groups (Bonferroni-corrected Chi-squared 
tests, total α = 0.05). In total, 8% of respondents with PsO alone 
and 4% of respondents with PsA ± PsO did not know or declined to 
answer
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who saw a dermatologist or rheumatologist at least annu-
ally (Fig. 4f). Absence rates were not significantly related 
gender (data not shown).
Figure 5 shows the negative impact of PsO and PsA on 
education and work for all the respondents. Only 41.6% of 
respondents with PsO alone reported a negative impact, 
compared to 77.5% of those with PsA ± PsO (Fig.  5a). 
Among respondents with non-severe symptoms of PsO and/
or PsA, a negative impact was reported by 34.5% (Fig. 5b). 
A negative impact of PsO and/or PsA was reported by a 
greater proportion of respondents who saw a dermatologist 
or rheumatologist at least annually compared with respond-
ents who saw these HCPs less frequently (Fig. 5f).
Discussion
Most respondents in the survey had seen a HCP within the 
past 3 years. The HCPs most frequently seen for PsO symp-
toms by respondents with PsO alone were GPs (35.5%) 
rather than dermatologists (29.5%). Similarly, in the MAPP 
study, 35% of respondents with PsO most frequently 
Fig. 3  Proportion of respondents reporting that their disease had a 
strong negative impact on various daily activities, split by diagno-
sis: psoriasis (PsO) alone and psoriatic arthritis (PsA) with or with-
out psoriasis (PsA ± PsO). The inset table shows the fraction of the 
respondents who reported zero, a few (1–3), or many (4 +) strong 
impacts. (Q14. To what extent do you agree that you have experi-
enced the following in the past 12 months due to your psoriasis/pso-
riatic arthritis? The chart shows the pooled results for boxes 4 + 5 
from a scale from 1 to 5 where 1 = do not agree at all and 5 = totally 
agree.) *Significant difference between PsO and PsA ± PsO groups 
(Bonferroni-corrected chi-squared tests, total α = 0.05). Respondents 
who answered “Do not know” were grouped with those not reporting 
a strong negative impact
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Fig. 4  Absence from work or school (where relevant, n = 1003) in 
the previous 12 months, split by: a diagnosis, psoriasis (PsO) alone 
or psoriatic arthritis (PsA) with or without psoriasis (PsA ± PsO), b 
perceived severity, c treatment type, d age group, e membership of 
a patient group, and f frequency of dermatologist/rheumatologist vis-
its. (Q16. Have you been absent from work or school in the past 12 
months due to your psoriasis/psoriatic arthritis?) *Significant differ-
ence between groups in each sub-chart (Bonferroni-corrected z tests, 
total α = 0.05)
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Fig. 5  Extent to which psoriasis (PsO)/psoriatic arthritis (PsA) had 
negatively impacted on respondent’s work/career or education, since 
they first developed symptoms (n = 1221). Split by: a diagnosis, PsO 
alone or PsA with or without PsO (PsA ± PsO), b perceived severity, 
c treatment type, d age group, e membership of a patient group, and 
f frequency of dermatologist or rheumatologist visits. (Q17. To what 
extent has your psoriasis/psoriatic arthritis had a negative impact on 
your work/career or education, since you first developed symptoms?) 
*Significant difference between groups in each sub-chart (Bonferroni-
corrected z tests, total α = 0.05)
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consulted a GP in both North America and in Europe [12]. 
A Swedish registry-based study found that nearly one-third 
of patients with PsO consulted only primary care physicians 
[14] and data from the US National PsO Foundation Sur-
vey suggests that about one quarter of patients with PsO 
mostly consult primary care physicians rather than a spe-
cialist [2]. Rheumatologists were most frequently consulted 
for PsA symptoms by approximately one-third of respond-
ents with PsA ± PsO and this is also consistent with the 
MAPP study [12]. Among respondents with PsA ± PsO, the 
perceived severity of PsA symptoms did not significantly 
alter the choice of physician; respondents with or without 
severe symptoms reported seeing rheumatologists more 
frequently than GPs. We were surprised to find that 10.7% 
of those reporting PsO alone and 14.3% of those reporting 
PsA ± PsO had never seen a dermatologist or a rheumatolo-
gist, respectively.
It was noted that there was a relatively high proportion of 
respondents with PsA ± PsO visiting an HCP to discuss side-
effects. This may be because respondents with PsA ± PsO 
generally had more severe disease [4], implying more 
potent treatment regimens with more potential side-effects; 
although, as we have previously reported, over one-third of 
respondents with severe symptoms had never discussed a 
systemic treatment with their physician [19]. It might also 
be an effect of the relatively high proportion of members of 
patient groups, who are likely to be more informed about 
potential side-effects, among respondents with PsA ± PsO.
As expected, and consistent with the previous studies 
in other geographical regions [1, 6, 12, 16], the reported 
impacts of disease on daily activities and on work or educa-
tion were greater for those with PsA ± PsO compared with 
PsO alone, and for those with severe symptoms compared 
with mild symptoms. Nevertheless, more than one-third of 
respondents with non-severe PsO and/or PsA reported that 
the condition had at least some negative impact on their 
work or education, emphasising the importance of appro-
priate support even for patients with more mild conditions.
A large proportion of respondents with PsA ± PsO indi-
cated that they suffered from sleeping disorders (44.5%) 
and depression and anxiety (34.9%): two impacts that are 
not included in the dermatology life quality index (DLQI). 
Thus, although it could be argued that comparison of our 
results with the other studies might be hampered, because 
we did not use a standard tool like the DLQI, the advantage 
of our approach is that we were able to identify two impor-
tant impacts that may otherwise have been overlooked. A 
recent case-controlled study carried out in Norway found 
that almost 50% of patients with PsO suffer from substan-
tial fatigue, which is not unusual in chronic inflammatory 
diseases [18]. In the MAPP study, 7% of respondents with 
PsA ± PsO mentioned lack of sleep as the reason for consid-
ering their condition to be severe [10]. A 2017 systematic 
review of the literature found that the most prevalent mental 
disorder in individuals with psoriasis was sleep disorders 
(average prevalence 62%), with anxiety (average prevalence 
30.4%) and depression (average prevalence 27.6%) also fre-
quently reported [7].
More than half of respondents (51.9%) with PsA ± PsO 
reported some absence from work or school over the past 
12  months. This is higher than the 31.5% reported for 
respondents with PsA in the MAPP survey [10]. This could 
be a reflection of the relatively generous level of sick-leave 
benefits and disability pensions provided in Scandinavian 
countries, particularly in Sweden and Norway [3]. Indeed, 
overall sickness absence from employment is relatively high 
in Sweden and Norway; 5.2% and 5.0%, respectively for 
1995–2003, compared with the European average of 2.8% 
[3]. Members of patient groups reported a greater impact on 
work/education since diagnosis (Fig. 5a) and more absences 
from work/education (Fig. 4a) than non-members, as did 
respondents who saw a HCP at least annually compared with 
those who visited their HCP less frequently. There may be 
some interaction between HCP contact, patient group mem-
bership, diagnosis, and disease severity: respondents with 
PsA ± PsO had more frequent HCP contact than those with 
PsO alone and patient group members were more likely to 
have a diagnosis of PsA ± PsO and were also more likely to 
have severe symptoms of PsO or PsA [4]. Respondents aged 
45–74 years reported lower negative impacts on their careers 
and fewer absences from work; this is compatible with the 
conclusions of a recent systematic review of studies from 
EU countries [16].
The generalisability of the NORAPP findings is limited 
by factors inherent to this type of respondent survey, includ-
ing a reliance on an accurate recall of facts and interpretation 
of questions. It is notable that a proportion of respondents 
had never seen a dermatologist or rheumatologist, raising the 
possibility that “physician-diagnosed” PsO or PsA could be 
wrong in some patients. A strength of the study is that, like 
the MAPP study, it did not rely on patient groups or clinical 
centres to identify or supply participants, but rather aimed 
to include a broadly representative cross-section of indi-
viduals living with PsO and PsA in Sweden, Denmark, and 
Norway. Due to the homogeneity between the Scandinavian 
countries when it comes to ethnicity and access to health-
care services, pooling of data was not an issue [11, 17]. 
The use of active sampling and weighting of results aimed 
to increase the representativeness of the study population. 
Nevertheless, the relatively high proportion of respondents 
who were members of patient groups (> 20%) could suggest 
an element of potential bias. YouGov panels are made up of 
a cross-section of individuals who have specifically opted 
in to participate in online studies; these individuals may 
be more likely to be members of patient groups. Given the 
differences that we observed between respondents who are 
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members of patient groups and those who are not, this factor 
should be considered when interpreting the survey results. 
The difference between these two subgroups highlights that 
the results of surveys based entirely on respondents sourced 
from patient groups should not be directly compared with 
broader population surveys. Furthermore, patient group 
membership should always be reported in surveys regard-
ing PsO and/or PsA.
In conclusion, the NORPAPP survey shows that PsO and 
PsA have a profound impact on the HRQoL and career/edu-
cation of individuals with these conditions in Sweden, Den-
mark, and Norway. The impact is greater among individuals 
with PsA ± PsO, suggesting the importance of appropriate 
monitoring of patients to ensure timely diagnosis and treat-
ment of PsA. Sleeping disorders and depression were found 
to affect the HRQoL of many respondents, particularly those 
with PsA ± PsO, and we recommend addressing these issues 
during consultations as they should not be overlooked. To 
this end, better training and education may be needed to 
help dermatologists, rheumatologists, and other HCPs who 
diagnose and manage these diseases to understand the psy-
chological impacts of PsO and PsA.
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